An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma

Summary

The purpose of this study is to evaluate the efficacy (effectiveness) and tolerability (how well a participant can stand a particular medicine or treatment; ability to be used) of bortezomib in combination with rituximab standard therapy (medicine or medical care given to a participant for a disease or condition) in participants with relapsed or refractory (not responding to treatment) follicular lymphoma (a cancer of the lymph nodes \[or tissues\] in follicle).

Timeline

Start

2006-02

Primary completion

2007-08

Completion

2007-08

Outcome

Outcome not reported

Stopped (Enrollment): “Recruitment too slow”

Drugs

Indications